G Protein Coupled Bile Acid Receptor 1 - Pipeline Review, H2 2019

G Protein Coupled Bile Acid Receptor 1 - Pipeline Review, H2 2019

Summary

According to the recently published report 'G Protein Coupled Bile Acid Receptor 1 - Pipeline Review, H2 2019'; G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) - G protein-coupled bile acid receptor 1 (GPBAR1) is a protein encoded by the GPBAR1 gene. It is a receptor for bile acid. Bile acid-binding induces its internalization, activation of extracellular signal-regulated kinase and intracellular cAMP production. It is involved in the suppression of macrophage functions by bile acids.

The report 'G Protein Coupled Bile Acid Receptor 1 - Pipeline Review, H2 2019' outlays comprehensive information on the G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 1 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Dermatology, Gastrointestinal and Undisclosed which include indications Type 2 Diabetes, Atopic Dermatitis (Atopic Eczema), Metabolic Syndrome, Obesity, Ulcerative Colitis and Unspecified.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1)
- The report reviews G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding G Protein Coupled Bile Acid Receptor 1 (G Protein Coupled Receptor GPCR19 or Membrane Type Receptor For Bile Acids or hBG37 or GPR131 or GPBAR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope